Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/aian.AIAN_1303_20 http://scihub22266oqcxt.onion/10.4103/aian.AIAN_1303_20 34446994!8370175!34446994     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34446994&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Ann+Indian+Acad+Neurol 2021 ; 24 (3): 339-346 Nephropedia Template TP {{tp|p=34446994|t=2021. Guillian--Barre Syndrome in Patients with SARS-CoV-2: A Multicentric Study from Maharashtra, India |pdf=|usr=}}{{34446994}} gab.com Text Guillian--Barre Syndrome in Patients with SARS-CoV-2: A Multicentric Study from Maharashtra, India JO: Ann Indian Acad Neurol http://www.kidney.de/pget.php?&tw=1&pmid=34446994 #FOAvip BACKGROUND: Guillian--Barre' Syndrome (GBS) has been shown to be associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The aim of our study was to study the clinical profile and outcomes of GBS in COVID-19 from the Western region of India, the State of Maharashtra. METHODS: This was a retrospective, multicenter observation study from different hospitals in Maharashtra beginning from March 2020 until November 2020. RESULTS: We report 42 patients with COVID-19 GBS. Mean age was 59 years (range, 24--85 years). 31/42 (73.8%) were men. GBS was the presenting symptom in 14/42 (33%), while six of them remained asymptomatic for COVID-19 despite positive SARS-CoV-2 on nasopharyngeal swab reverse transcriptase polymerase chain reaction. The median interval between COVID-19 and GBS was 14 days (SD + 11), with minimum of 1 and maximum 40 days. Clinical presentation was like that of typical GBS. Electrophysiological studies showed a predominant demyelinating pattern in 25/42 (59.5%). Inflammatory markers were elevated in 35/42 (83.3%) and 38/42 (90.5%) had an Abnormal high-resolution CT (HRCT) chest. 14/42 (33.3%) patients required a ventilator, with nine deaths. Intravenous immunoglobulin was the mainstay of treatment for GBS. Majority had a good outcome and were walking independently or with minimal support at discharge. In subgroup analysis, the postinfectious group had a better outcome than the parainfectious group. CONCLUSION: GBS in COVID-19 occurs as both parainfectious and postinfectious GBS. Parainfectious GBS needs more rigorous monitoring and may benefit from COVID-19 specific treatment. Routine screening for SARS-CoV-2 should be implemented in patients with GBS in view of the ongoing pandemic. Twit Text FOAVip Guillian--Barre Syndrome in Patients with SARS-CoV-2: A Multicentric Study from Maharashtra, India ????Ann Indian Acad Neurol http://www.kidney.de/pget.php?&tw=1&pmid=34446994 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34446994 #FOAvip English Wikipedia <ref>{{Cite pmid|34446994}}</ref> Guillian--Barre Syndrome in Patients with SARS-CoV-2: A Multicentric Study from Maharashtra, India #MMPMID34446994 Dhamne MC; Benny R; Singh R; Pande A; Agarwal P; Wagh S; Oak P; Lakhotia A; Godge Y; Bolegave V; Doshi D; Patidar Y; Venkatachalam A; Pujara B; Borse S; Makhija P; Khadilkar S Ann Indian Acad Neurol 2021[May]; 24 (3): 339-346 PMID34446994show ga BACKGROUND: Guillian--Barre' Syndrome (GBS) has been shown to be associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The aim of our study was to study the clinical profile and outcomes of GBS in COVID-19 from the Western region of India, the State of Maharashtra. METHODS: This was a retrospective, multicenter observation study from different hospitals in Maharashtra beginning from March 2020 until November 2020. RESULTS: We report 42 patients with COVID-19 GBS. Mean age was 59 years (range, 24--85 years). 31/42 (73.8%) were men. GBS was the presenting symptom in 14/42 (33%), while six of them remained asymptomatic for COVID-19 despite positive SARS-CoV-2 on nasopharyngeal swab reverse transcriptase polymerase chain reaction. The median interval between COVID-19 and GBS was 14 days (SD + 11), with minimum of 1 and maximum 40 days. Clinical presentation was like that of typical GBS. Electrophysiological studies showed a predominant demyelinating pattern in 25/42 (59.5%). Inflammatory markers were elevated in 35/42 (83.3%) and 38/42 (90.5%) had an Abnormal high-resolution CT (HRCT) chest. 14/42 (33.3%) patients required a ventilator, with nine deaths. Intravenous immunoglobulin was the mainstay of treatment for GBS. Majority had a good outcome and were walking independently or with minimal support at discharge. In subgroup analysis, the postinfectious group had a better outcome than the parainfectious group. CONCLUSION: GBS in COVID-19 occurs as both parainfectious and postinfectious GBS. Parainfectious GBS needs more rigorous monitoring and may benefit from COVID-19 specific treatment. Routine screening for SARS-CoV-2 should be implemented in patients with GBS in view of the ongoing pandemic. ?Guillian--Barre Syndrome in Patients with SARS-CoV-2: A Multicentric (epmc).pdf DeepDyve Pubget Overpricing